The Year in Neurology, 2011 Drug approvals and New treatments for Neurological disorders?

Medscape Article: 

Andrew N. Wilner, MD writes about the recent developments in basic science and clinical medicine to treat some of the impending neurological diseases, including several FDA approval on new drugs, interesting article.

A Look Back: Introduction

2011 has been a very exciting year for neurologists and their patients. Advances in basic science and disciplined clinical trials have led to drug approvals for the prevention of stroke and treatment of epilepsy. In addition, at least 2 oral drugs for relapsing-remitting multiple sclerosis, BG-12 and teriflunomide, boast positive results from phase 3 trials and are poised for approval by the US Food and Drug Administration (FDA).
In 2010, the FDA approved dabigatran, a thrombin inhibitor, for anticoagulation in patients with nonvalvular atrial fibrillation. In November 2011, the FDA approved rivaroxaban, a once-daily oral factor Xa inhibitor, for the same indication. Another factor Xa inhibitor, apixaban, recently demonstrated superior results to warfarin in preventing stroke or systemic embolism, with less bleeding and lower mortality, and may soon be approved as well.^{[1]
Full article at Medscape linked at the top.} 

Wave P300 (ERP) & Temporal Lobe Epilepsey

In this latest issue of the journal of Human Brain Mapping, the authors suggest that wave P300 an endogenous event related evoked potential seems to be altered in pateints with temporal lobe epilepsy, a change in the latency and amplitude of P300 was observed in 10 patients suffering from TLE (same number of normal recording was conduted for comparison). 

Hum Brain Mapp. 2008 Nov 25. [Epub ahead of print] 

Attention impairment in temporal lobe epilepsy: A neurophysiological approach via analysis of the P300 wave.

Bocquillon P, Dujardin K, Betrouni N, Phalempin V, Houdayer E, Bourriez JL, Derambure P, Szurhaj W.
Department of Clinical Neurophysiology, Lille University Medical Center, Lille, France.
Purpose:

Attention is often impaired in temporal lobe epilepsy (TLE). The P300 wave (an endogenous, event-related potential) is a correlate of attention which is usually recorded during an "oddball paradigm," where the subject is instructed to detect an infrequent target stimulus presented amongst frequent, standard stimuli.

Modifications of the P300 wave's latency and amplitude in TLE have been suggested, but it is still not known whether the source regions also differ. Our hypothesis was that temporal lobe dysfunction would modify the P3 source regions in TLE patients. Methods: A comparative, high density, 128-channel electroencephalographic analysis of the characteristics of P300 (P3b latency and amplitude) was performed in 10 TLE patients and 10 healthy controls during auditory and visual oddball paradigms. The P3b sources were localized on individual 3D MR images using the LORETA method and intergroup statistical comparisons were performed using SPM2(R) software. Results: Our main results (in both individual analyses and intergroup comparisons) revealed a reduction in temporal (and more particularly mesiotemporal) sources and, to a lesser extent, frontal sources in TLE patients, compared with controls. Discussion: This reduction may reflect direct, local cortical dysfunction caused by the epileptic focus or more complex interference between epileptic networks and normal attentional pathways. Hum Brain Mapp, 2009. (c) 2008 Wiley-Liss, Inc.

PMID: 19034898 [PubMed - as supplied by publisher]